Ken Fisher Bei Gene, Ltd. Transaction History

Fisher Asset Management, LLC

  • $243 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Dec 12, 2023
BUY
$178.3 - $266.78 $379,065 - $567,174
2,126 New
2,126 $379,000
Q2 2023

Aug 08, 2023
SELL
$178.3 - $266.78 $40,295 - $60,292
-226 Reduced 9.61%
2,126 $379,000
Q1 2023

Dec 12, 2023
BUY
$215.53 - $274.5 $419,205 - $533,902
1,945 New
1,945 $419,000
Q1 2023

May 01, 2023
BUY
$215.53 - $274.5 $156,690 - $199,561
727 Added 44.74%
2,352 $507,000
Q4 2022

Feb 03, 2023
BUY
$125.51 - $229.3 $125 - $229
1 Added 0.06%
1,625 $357,000
Q3 2022

Nov 08, 2022
SELL
$131.8 - $202.24 $227,355 - $348,864
-1,725 Reduced 51.51%
1,624 $219,000
Q2 2022

Aug 09, 2022
BUY
$121.11 - $216.05 $242 - $432
2 Added 0.06%
3,349 $542,000
Q1 2022

May 05, 2022
SELL
$146.52 - $269.56 $8,058 - $14,825
-55 Reduced 1.62%
3,347 $631,000
Q4 2021

Feb 02, 2022
SELL
$248.56 - $389.34 $98,678 - $154,567
-397 Reduced 10.45%
3,402 $922,000
Q3 2021

Oct 26, 2021
SELL
$249.6 - $403.14 $33,696 - $54,423
-135 Reduced 3.43%
3,799 $1.38 Million
Q2 2021

Jul 27, 2021
BUY
$292.75 - $367.01 $678,594 - $850,729
2,318 Added 143.44%
3,934 $1.35 Million
Q1 2021

Apr 27, 2021
BUY
$260.64 - $382.12 $260 - $382
1 Added 0.06%
1,616 $562,000
Q4 2020

Jan 29, 2021
BUY
$221.31 - $316.61 $357,415 - $511,325
1,615 New
1,615 $417,000

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.7B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email